QX39

QX39
Identifiers
	IUPAC name N-(4-(6-chloroquinoxalin-2-yl)phenyl)acetamide;
CAS Number	1798331-71-1;
PubChem CID	91809172;
CompTox Dashboard (EPA)	DTXSID101336839 ;
Chemical and physical data
Formula	C20H14ClNO
Molar mass	319.79 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C(=NC2=C(O1)C=C(C=C2)Cl)C3=CC=C(C=C3)C4=CC=CC=C4;
	InChI InChI=1S/C20H14ClNO/c21-17-10-11-18-20(12-17)23-13-19(22-18)16-8-6-15(7-9-16)14-4-2-1-3-5-14/h1-12H,13H2; Key:RJFBVAUZKPHMJI-UHFFFAOYSA-N;

QX39 (Compound A, CA39) is a synthetic compound that activates chaperone-mediated autophagy (CMA) by increasing the expression of the lysosomal receptor for this pathway, LAMP2A lysosomes. It showed potent activity in vitro but has poor pharmacokinetic properties and was not suitable for animal research. Subsequent research led to the development of CA77.1, a CMA activator suitable for in vivo use.^[1]^[2]^[3]^[4]^[5]

References

^ Anguiano J, Garner TP, Mahalingam M, Das BC, Gavathiotis E, Cuervo AM (June 2013). "Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives". Nature Chemical Biology. 9 (6): 374–82. doi:10.1038/nchembio.1230. PMC 3661710. PMID 23584676.
^ US 9512092, Cuervo AM, Gavathiotis E, Xin Q, Das BC, "Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof", published 18 June 2015, assigned to Albert Einstein College of Medicine of Yeshiva
^ WO 2020077024, Cuervo AM, Gavathiotis E, "Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators", published 16 April 2020, assigned to Albert Einstein College of Medicine of Yeshiva
^ Bourdenx M, Martín-Segura A, Scrivo A, Rodriguez-Navarro JA, Kaushik S, Tasset I, et al. (April 2021). "Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome". Cell. 184 (10): 2696–2714.e25. doi:10.1016/j.cell.2021.03.048. PMC 8152331. PMID 33891876.
^ Cuervo AM, et al. Compounds Useful as Chaperone-Mediated Autophagy Modulators. Patent WO 2020/046335

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Anguiano J, Garner TP, Mahalingam M, Das BC, Gavathiotis E, Cuervo AM (June 2013). "Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives". Nature Chemical Biology. 9 (6): 374–82. doi:10.1038/nchembio.1230. PMC 3661710. PMID 23584676.

[2] US 9512092, Cuervo AM, Gavathiotis E, Xin Q, Das BC, "Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof", published 18 June 2015, assigned to Albert Einstein College of Medicine of Yeshiva

[3] WO 2020077024, Cuervo AM, Gavathiotis E, "Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators", published 16 April 2020, assigned to Albert Einstein College of Medicine of Yeshiva

[Bourdenx_2021-4] Bourdenx M, Martín-Segura A, Scrivo A, Rodriguez-Navarro JA, Kaushik S, Tasset I, et al. (April 2021). "Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome". Cell. 184 (10): 2696–2714.e25. doi:10.1016/j.cell.2021.03.048. PMC 8152331. PMID 33891876.

[5] Cuervo AM, et al. Compounds Useful as Chaperone-Mediated Autophagy Modulators. Patent WO 2020/046335

[1]

[2]

[3]

[4]

[5]